156 research outputs found

    Synthesis and characterization of erbium trioxide nanoparticles as photocatalyzers for degradation of methyl orange dye

    Get PDF
    The present work focuses on the photocatalytic degradation of methyl orange (MO) on erbium trioxide nanoparticles (Er2O3 NPs). In this study, Er2O3 nanoparticles were synthesized and fully characterized via various techniques, including X-ray diffraction, UV–visible spectroscopy and scanning electron microscopy techniques. The results revealed that the photocatalytic activity of the prepared Er2O3 NPs was manifested in MO photodegradation. The optimum efficiency obtained was 16&thinsp;%.</p

    Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer

    Get PDF
    IntroductionThere is no consensus chemotherapy regimen with concurrent radiotherapy (RT) for inoperable stage IIIA/B non–small-cell lung cancer. This trial evaluated pemetrexed with carboplatin (PCb) or cisplatin (PC) with concurrent RT followed by consolidation pemetrexed.MethodsIn this open-label, noncomparative phase II trial, patients with inoperable stage IIIA/B non–small-cell lung cancer (initially all histologies, later restricted to nonsquamous) were randomized (1:1) to PCb or PC with concurrent RT (64–68 Gy over days 1–45). Consolidation pemetrexed monotherapy was administered every 21 days for three cycles. Primary endpoint was 2-year overall survival (OS) rate.ResultsFrom June 2007 to November 2009, 98 patients were enrolled (PCb: 46; PC: 52). The 2-year OS rate was PCb: 45.4% (95% confidence interval [CI], 29.5–60.0%); PC: 58.4% (95% CI, 42.6–71.3%), and in nonsquamous patients was PCb: 48.0% (95% CI, 29.0–64.8%); PC: 55.8% (95% CI, 38.0–70.3%). Median time to disease progression was PCb: 8.8 months (95% CI, 6.0–12.6 months); PC: 13.1 months (95% CI, 8.3–not evaluable [NE]). Median OS (months) was PCb: 18.7 (95% CI, 12.9–NE); PC: 27.0 (95% CI, 23.2–NE). The objective response rates (ORRs) were PCb: 52.2%; PC: 46.2%. Grade 4 treatment-related toxicities (% PCb/% PC) were: anemia, 0/1.9; neutropenia, 6.5/3.8; thrombocytopenia, 4.3/1.9; and esophagitis, 0/1.9. Most patients completed scheduled chemotherapy and RT during induction and consolidation phases. No drug-related deaths were reported during chemoradiotherapy.ConclusionsBecause of study design, efficacy comparisons cannot be made. However, both combinations with concurrent RT were active and well tolerated

    ECOG-ACRIN (E4805) Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients with Metastatic Renal Cell Carcinoma

    Get PDF
    Background—Aflibercept is a recombinantly-produced fusion protein that has potent anti-VEGF activity. We tested whether aflibercept has clinical activity in clear cell renal cell carcinoma (ccRCC). The recommended Phase 2 dose was 4 mg/kg but several patients treated at 1 mg/kg demonstrated prolonged progression-free survival (PFS). We therefore tested both doses in a parallel group randomized trial. Methods—Eligible patients (pts) had histologically confirmed advanced or metastatic ccRCC and previous treatments including prior exposure to a VEGF RTKI. Patients received aflibercept (either 1 mg/kg or 4 mg/kg) day 1 of a 14-day cycle until progression. Patients randomized to 1 mg/kg could crossover to 4 mg/kg at progression. The primary endpoint was proportion alive and progression-free at 8 weeks. A Simon 2-stage design was used for each arm with 33 and 24 eligible pts/arm enrolled in stages 1 and 2. Results—94 pts were enrolled, 59 and 35 to 4 mg and 1 mg doses, respectively. 72% had 1 prior tx most commonly sunitinib. 16 eligible pts crossed over at progression to the 4 mg dose. Most common adverse events were hypertension, proteinuria, and fatigue. Only 4 pts reported Grade 4 or higher toxicity. With 36/59 (61%) pts PFS at 8 wks, the 4-mg/kg dose met protocol specified efficacy criteria. Conclusions—Aflibercept is active in previously treated ccRCC and may be worthy of further study

    Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    Get PDF

    Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy

    Full text link
    Premature ovarian failure is a devastating long-term toxic effect of chemotherapy for premenopausal women. The survival benefit of adjuvant chemotherapy in young women with operable hormone receptor–negative breast cancer is well known, but concern over becoming infertile may influence the choice of treatment for many women. A number of trials have investigated the combined use of a gonadotropin-releasing hormone (GnRH) agonist and adjuvant chemotherapy in an attempt to protect ovarian function in premenopausal women. Results of such studies were mixed, and there were few data on pregnancy outcomes. The aim of this randomized trial was to determine whether administration of the GnRH agonist goserelin with chemotherapy would reduce the rate of ovarian failure after adjuvant or neoadjuvant treatment of hormone-receptor–negative early-stage breast cancer. A total of 257 premenopausal women with operable hormone receptor–negative breast cancer were randomized to receive standard chemotherapy with goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The rate of ovarian failure at 2 years was the primary study end point. Ovarian failure was defined as the absence of menses for the preceding 6 months and follicle-stimulating hormone levels in the postmenopausal range at 2 years. Conditional logistic regression was used to compare rates. Secondary end points evaluated included pregnancy outcomes and disease-free and overall survival. Of the 257 patients, 218 were eligible and could be evaluated: 113 in the chemotherapy-alone group and 105 in the goserelin group. Complete primary end-point data were available for 135 of the 218 patients who could be evaluated. Among these, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group; the odds ratio was 0.30, with a 95% confidence interval of 0.09 to 0.97; 2-sided P = 0.04. To determine the effect of the missing primary end-point data on the main study findings, sensitivity analyses were performed. The results of these analyses showed that the missing data had no significant effect on the association between treatment and stratification variables (age and planned chemotherapy regimen). Among the 218 patients who could be evaluated, more women became pregnant in the goserelin group than in the chemotherapy-alone group (21% vs 11%, P = 0.03). Kaplan-Meier curves showed that more women in the goserelin group had improved disease-free survival (P = 0.04) and overall survival (P = 0.05). Consistent with the findings of previous randomized trials, these data suggest that administration of a GnRH agonist with chemotherapy protects ovarian function, reducing the risk of early menopause and improving prospects for fertility. Although missing primary-end-point data weaken interpretation of the findings, there is no evidence that the missing data influenced the relative comparison between randomized groups

    Microscopic calculations of quadrupole moments in Li and B isotopes

    No full text
    Quadrupole moments and effective charges are calculated for Li (A = 7, 8, 9, 11) and B (A = 8, 10, 11, 12, 13, 14, 15) isotopes based on the shell model with p and large basis spsdpf-shell model spaces. Excitations out of major shell space are taken into account through a microscopic theory which allows particle-hole excitations from the core and model space orbits to all higher orbits with 6ħω excitations. Effective charges are obtained for the neutron-rich Li and B isotopes which are smaller than the standard values for the stable p- and sd-shell nuclei. Our calculated Q moments agree very well with the experimentally observed trends of the recent experimental data

    THE HIGH RESOLUTION INFRARED SPECTRUM OF 2ν3(ℓ=0) 12CD3F†2\nu_{3} (\ell=0)\ ^{12}CD_{3}F^\dag

    No full text
    †^{\dag}supported in part by the planetary Atmospheres program of the National Aeronautics and Space Administration {Grant NGL-43-001-006).Author Institution:The parallel component of the 2ν32\nu_{3} band of 12CD3F^{12}CD_{3}F has been recorded with a resolution of 20−25×10−320-25 \times 10^{-3} cm−1cm^{-1}. The (αB−αA)(\alpha^{B}- \alpha^{A}) term is small and therefore the J-manifolds are unresolved for J<15 < 15 and only partially resolved for greater J values. The band has been analyzed using standard techniques and preliminary values of ν0=1977.178(3)\nu_{0}=1977.178(3) cm−1cm^{-1} and αB=(B′′−B′)=3.086(7)×10−3\alpha^{B}=(B^{\prime\prime}-B^{\prime})=3.086(7) \times 10^{-3} cm−1cm^{-1} have been obtained. A value of 2.85(5)×10−32.85(5) \times 10^{-3} cm−1cm^{-1} has been obtained for αA\alpha^{A} form a band contour fit to the P(10) multiple. Details of the analysis and further results will be reported
    • …
    corecore